Variable | Hospital decedents (n = 639) | Hospital survivors (n = 414) | P value |
---|---|---|---|
Male gender | 404 (63.2%) | 287 (69.3%) | 0.05 |
Age (years) | 63 [55–71] | 63 [53–71] | 0.29 |
Type of malignancy | |||
Lung | 157 (24.6%) | 45 (10.9%) | < 0.001 |
Colorectal | 90 (14.1%) | 88 (21.3%) | |
Breast | 68 (10.6%) | 61 (14.7%) | |
Head and neck | 79 (12.4%) | 46 (11.1%) | |
Others | 245 (38.4%) | 174 (42.0%) | |
Diagnosis to ICU (months) | 3 [1–14] | 6 [1–36] | |
Cancer status | 0.002 | ||
Complete remission | 99 (15.5%) | 90 (21.8%) | – |
Partial remission | 92 (14.4%) | 51 (12.4%) | 0.004 |
Diagnosis during ICU stay | 52 (13.0%) | 19 (7.5%) | 0.04 |
Distant metastases | 384 (60.1%) | 177 (42.8%) | < 0.001 |
Severity at ICU admission | |||
SAPS II | 54 [42–72] | 39 [30–50] | < 0.001 |
SOFA | 8 [5–12] | 4 [2–7] | < 0.001 |
Treatments during ICU stay | |||
Invasive mechanical ventilation | 518 (81.3%) | 203 (49.0%) | < 0.001 |
Vasopressors and/or inotropic drug | 403 (63.1%) | 126 (30.5%) | < 0.001 |
Renal replacement therapy | 127 (19.9%) | 41 (10.0%) | < 0.001 |
Cancer chemotherapy | 27 (4.4%) | 13 (3.3%) | 0.48 |
Neutropenia during ICU stay | 52 (8.2%) | 18 (4.4%) | 0.02 |